Based on cisplatin induced AKI, a HK-2 cell model was established by siRNA transfection silencing RPL11, while in vivo kidney targeted silencing was achieved using LyP-1 modified nanoparticles encapsulating si-RPL11. This evidence concerns the gene PTPN22 and acute kidney injury.